2 suspended. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Suspended 2 |
| Phase 1 | 1 | Suspended 1 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease PBKR03 - Leukodystrophy, Globoid Cell | Phase 1 / Phase 2 | Suspended | Gemma Biotherapeutics | 24 | 2022-02-24 | 2026-06-30 |
| Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD - Relapsing Forms of Multiple Sclerosis | Phase 2 | Suspended | Emerald Health Pharmaceuticals | 50 | 2021-10-19 | 2022-10-21 |
Autoimmune Diseases of the Nervous System (1) · Leukodystrophy, Globoid Cell (1) · Lysosomal Storage Diseases (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Nervous System Diseases (1) · Rare Diseases (1)
Autoimmune Diseases (1) · Brain Diseases (1) · Brain Diseases, Metabolic (1) · Brain Diseases, Metabolic, Inborn (1) · Central Nervous System Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Demyelinating Autoimmune Diseases, CNS (1) · Disease Attributes (1) · Genetic Diseases, Inborn (1) · Hereditary Central Nervous System Demyelinating Diseases (1) · Immune System Diseases (1) · Leukoencephalopathies (1) · Lipid Metabolism Disorders (1) · Lipid Metabolism, Inborn Errors (1)
Emerald Health Pharmaceuticals (1) · Gemma Biotherapeutics (1)
United States (2) · Australia (1) · Brazil (1) · Canada (1) · Israel (1) · Netherlands (1) · United Kingdom (1)
May Orfali, MD (1)